In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
News|Podcasts|September 21, 2026
ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
video interview prior to DPHARM 2026 , Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation, from building trust between patients and sites to where AI may and may not have a role in that relationship. Understanding that distinction—where human connection matters most versus where technology can help—is critical to genuine patient engagement. - In a
contributed article , Jason Makuch of IQVIA examined how only one in five life sciences organizations are scaling AI and seeing measurable value, because disconnected AI tools create silos instead of reducing them. A platform-based approach connects AI across workflows and governance, bringing AI into the tools employees already use rather than requiring them to switch between systems. - The
FDA approved Fayuvi as the first therapy for Sanfilippo syndrome type A , a rare genetic disease that progressively damages children's brains and nervous systems. Administered as a single infusion using gene therapy to deliver a missing enzyme, Fayuvi-treated patients in clinical trials maintained or improved cognitive function compared to an untreated historical comparison group, diverging from the expected disease course of decline during early childhood.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research.
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools.
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.
In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement more than gamification, and FDA permanent leadership appointments prioritizing regulatory predictability.
Trending on Applied Clinical Trials Online
1
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
2
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
3
How a Platform Approach Can Scale AI’s Impact in Life Sciences
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5